Results 141 to 150 of about 1,466,333 (379)

A Comprehensive Review on Capillary Electrophoresis–Mass Spectrometry in Advancing Biomolecular Research

ELECTROPHORESIS, EarlyView.
ABSTRACT This review provides an in‐depth exploration of capillary electrophoresis–mass spectrometry (CE–MS) in biomolecular research from 2020 to 2024. CE–MS emerges as a versatile and powerful tool due to its numerous advantages, facilitating the analysis of various biomolecules, including proteins, peptides, oligonucleotides, and other metabolites ...
Laura Pont, María Vergara‐Barberán, Enrique Javier Carrasco‐Correa   +2 more
wiley   +1 more source

Bispecific Antibodies Against HIV [PDF]

Cell, 2016
Synergistic bispecific antibodies against HIV exhibit extraordinary potency and breadth of neutralization as promising candidates for treatment and prevention.
openaire   +3 more sources

Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition

Journal of Immunology Research, 2016
Innovative strategies are necessary to maximize the clinical application of HIV neutralizing antibodies. To this end, bispecific constructs of human antibody F240, reactive with well-conserved gp41 epitope and antibody 14A8, reactive with the IgA ...
Xiaocong Yu, Mark Duval, Melissa Gawron, Marshall R. Posner, Lisa A. Cavacini   +4 more
doaj   +1 more source

Quantifying Critical Quality Attributes of Protein Therapeutics by Sodium Dodecyl Sulfate–Capillary Gel Electrophoresis With Native Fluorescence Detection

ELECTROPHORESIS, EarlyView.
ABSTRACT In the biopharmaceutical industry, the sodium dodecyl sulfate–capillary gel electrophoresis (SDS–CGE) assay is often used to assess therapeutic critical quality attributes (CQAs). Traditional detection methods for SDS–CGE methods, such as ultraviolet (UV) absorbance and laser‐induced fluorescence (LIF), are widely used but come with ...
Zaifang Zhu
wiley   +1 more source

Exploring the Potential and Advancements of Circular RNA Therapeutics

Exploration, EarlyView.
Given the remarkable advantages in terms of stability, sustained expression profile, safety, wide range of druggable targets, scalable and cost‐effective manufacturing capabilities, circRNA is currently undergoing intensive investigation for various therapeutic applications such as vaccines, protein replacement, genetic disease treatment, gene therapy,
Lei Wang, Lianqing Wang, Chunbo Dong, Jialong Liu, Guoxin Cui, Shan Gao, Zhida Liu   +6 more
wiley   +1 more source

Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody

Cancer Management and Research, 2023
Darren Pan, Joshua Richter Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USACorrespondence: Darren Pan, One Gustave L.
Pan D, Richter J
doaj  

BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells

Translational Oncology, 2017
Among different cancer immunotherapy approaches, bispecific antibodies (BsAbs) are of great interest due to their ability to recruit immune cells to kill tumor cells directly.
Jieyu Xing, Limin Lin, Jing Li, Jiayu Liu, Changhua Zhou, Haitao Pan, Rui Shu, Bin Dong, Donglin Cao, Qing Li, Zhong Wang   +10 more
doaj   +1 more source

Identification and characterization of nanobodies targeting the EphA4 receptor [PDF]

, 2017
The ephrin receptor A4 (EphA4) is one of the receptors in the ephrin system that plays a pivotal role in a variety of cell-cell interactions, mostly studied during development. In addition, EphA4 has been found to play a role in cancer biology as well as
Chavez-Gutierrez, Lucia, Curnock, Adam, De Strooper, Bart, Dewilde, Maarten, Hassanzadeh-Ghassabeh, Gholamreza, Haustraete, Jurgen, Joyce, Peter, Lemmens, Robin, Little, Susan, Robberecht, Wim, Roucourt, Bart, Rue, Laura, Schoonaert, Lies, Timmers, Mieke, Van Damme, Philip, Van den Bosch, Ludo, Weber, Peter   +16 more
core   +2 more sources

Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. [PDF]

, 1993
Louis M. Weiner, Michele Holmes, A Richeson, Antony Godwin, Gregory P. Adams, Sylvia T. Hsieh-Ma, David B. Ring, R. Katherine Alpaugh   +7 more
openalex   +1 more source

First‐Line Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective, Multicenter, Real‐World Study

Head &Neck, EarlyView.
ABSTRACT Background In Europe, pembrolizumab with or without chemotherapy is the recommended first‐line treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), with a combined positive score (CPS) ≥ 1. In France, the TPExtreme (TPEx) regimen is preferred for CPS < 1.
Alizée Simon, Cyril Abdeddaim, DucTrung Nguyen, Patrice Gallet, Didier Peiffert, Aurélien Lambert, Lionnel Geoffrois   +6 more
wiley   +1 more source